Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of ad spending from open exchanges to closed platforms, which limited its technological capabilities [5]. - It is claimed that DoubleVerify's ability to monetize its high-margin advertising optimization services was significantly hampered due to the high costs and time required for technology development for closed platforms [5]. - The lawsuit also states that DoubleVerify's competitors were better positioned to integrate AI into their offerings, negatively impacting DoubleVerify's competitive edge and profitability [5]. - Additional allegations include systematic overbilling of customers for ad impressions served to declared bots and misleading risk disclosures that characterized adverse facts as mere possibilities [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [5]. - When the true details became public, investors reportedly suffered damages due to the misleading information [5].

Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, alleging that the company made false statements regarding its partnership with McDonald's and the demand for its products, leading to significant financial losses for investors [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Krispy Kreme securities between March 26, 2024, and May 7, 2025 [1]. - Investors have until July 15, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. - The lawsuit claims that demand for Krispy Kreme products declined significantly at McDonald's locations after the initial marketing launch [3]. Group 2: Financial Performance - Krispy Kreme reported net revenue of $375.2 million for the first quarter of 2025, representing a decline of 15.3% compared to the previous year [4]. - The company also reported a net loss of $33.4 million, compared to a net loss of $6.7 million in the prior year [4]. - Following the release of these financial results, Krispy Kreme's share price fell by nearly 25% [4]. Group 3: Partnership with McDonald's - Krispy Kreme and McDonald's expanded their partnership nationwide starting in the second half of 2024, following a small-scale test in 2022 [2]. - The lawsuit alleges that the partnership was not profitable and posed a substantial risk to maintaining the collaboration with McDonald's [3]. - Krispy Kreme announced it is reassessing its deployment schedule with McDonald's and has withdrawn its prior full-year outlook due to uncertainty around the partnership [4].

NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Funko, Inc. ("Funko" or the "Company") (NASDAQ: FNKO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Funko and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 7, 2025, Funko announced ...

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation, alleging that the company misled investors regarding the impact of the termination of its acquisition by Amazon and the effectiveness of its restructuring plan [1][2][3]. Group 1: Allegations and Company Actions - iRobot and Amazon mutually agreed to terminate the acquisition in January 2024, yet iRobot claimed confidence in its ability to operate successfully as a standalone company [2][3]. - Following the acquisition termination, iRobot announced a restructuring plan, referred to as "iRobot Elevate," aimed at stabilizing the company and focusing on profitability and market share growth [2][3]. - On March 12, 2025, iRobot reported disappointing financial results for Q4 and the full year of 2024, leading to a significant drop in stock price by $3.255 per share, or 51.58%, closing at $3.055 per share [2][3]. Group 2: Financial Stability Concerns - The lawsuit alleges that iRobot overstated the effectiveness of its restructuring plan and that it was unlikely to operate profitably as a standalone entity, raising doubts about its ability to continue as a going concern [3].

Core Viewpoint - A securities class action lawsuit has been filed against XPLR Infrastructure, LP, alleging misleading statements and omissions regarding the company's financial condition and business model during the class period from September 27, 2023, to January 27, 2025 [1][3]. Company Overview - XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, focuses on acquiring, owning, and managing contracted clean energy projects in the United States, including wind and solar power projects and a natural gas pipeline [2]. Allegations in the Class Action - The lawsuit claims that during the class period, the defendants made misleading statements about XPLR's operations as a yieldco, which is a business model focused on delivering cash distributions to investors [3]. - Specific allegations include: - XPLR was struggling to maintain its yieldco operations [3]. - Defendants entered financing arrangements to temporarily alleviate operational issues while downplaying associated risks [3]. - The company could not resolve these financings before maturity without risking significant unitholder dilution [3]. - Defendants planned to halt cash distributions to redirect funds to resolve financing issues [3]. - The yieldco business model and distribution growth rate were deemed unsustainable [3]. - Public statements made by the defendants were materially false and misleading [3]. Market Reaction - On January 28, 2025, XPLR announced it would suspend cash distributions to common unitholders and abandon its yieldco model, leading to a significant drop in the stock price from $15.80 to $10.49 per unit, a decline of nearly 35% [4].

Core Points - Holzer & Holzer, LLC is investigating Capricor Therapeutics, Inc. for potential compliance issues with federal securities laws following the receipt of a Complete Response Letter from the FDA regarding its Biologics License Application for Deramiocel [1] - The announcement of the CRL led to a decline in Capricor's stock price [1] Company Information - Capricor Therapeutics, Inc. trades on NASDAQ under the ticker CAPR [1] - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Elevance Health, Inc. common stock about the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Group 1: Class Action Details - Investors who purchased Elevance common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 11, 2025 [2]. - The lawsuit alleges that Elevance made false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. Group 2: Allegations Against Elevance - The lawsuit claims that Elevance misrepresented its monitoring of cost trends associated with the Medicaid redetermination process, assuring investors that premium rates were sufficient to address risks [4]. - It is alleged that the acuity and utilization of Elevance's Medicaid members rose significantly, contrary to the company's assurances, leading to damages for investors when the truth was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against iRobot Corporation for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 5, 2025 [3][5]. Group 1: Allegations Against iRobot - The complaint alleges that iRobot and its executives made false and misleading statements regarding the effectiveness of the Restructuring Plan following the termination of the Amazon Acquisition [5]. - It is claimed that iRobot overstated its ability to operate profitably as a standalone company, raising substantial doubt about its ability to continue as a going concern [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for Q4 and full year 2024, marking a 44% year-over-year decline [6]. - The company expressed uncertainty regarding the success of new product launches due to various factors, including consumer demand and macroeconomic conditions, indicating substantial doubt about its financial viability for at least 12 months [6]. Group 3: Market Reaction - Following the announcement of its financial results, iRobot's stock price fell by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [7].

Core Viewpoint - Robbins LLP is investigating Kindercare Learning Companies, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1]. Group 1: Company Overview - Kindercare Learning Companies, Inc. provides early childhood education and care services in the United States [1]. Group 2: Legal Investigation - The investigation by Robbins LLP aims to determine if there were any violations of securities laws by Kindercare's officers and directors [1]. - Shareholders who have lost money in their investment in Kindercare are encouraged to contact Robbins LLP for more information about their rights [2]. Group 3: Robbins LLP Background - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, having obtained over $1 billion for shareholders [3].